EC
ARCT icon

EntryPoint Capital’s Arcturus Therapeutics ARCT Stock Holding History

EntryPoint Capital’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,205
Closed -$297K – 643
2024
Q2 		$297K Buy
+12,205
New +$370K 0.14% 188

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EntryPoint Capital's ARCT Position: Q3 2024 in Review

EntryPoint Capital sold out of Arcturus Therapeutics (ARCT) in Q3 2024, closing a stake of 12,205 shares — an estimated $297K sold.

EntryPoint Capital first reported a position in ARCT in Q2 2024 and held it in 1 quarter. The position peaked at $297K in Q2 2024. 164 funds tracked by Wall St. Rank hold ARCT as of Q3 2024.

  • EntryPoint Capital reported no remaining Arcturus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • EntryPoint Capital sold 12,205 Arcturus Therapeutics shares in Q3 2024, an estimated $297K.
  • EntryPoint Capital first reported a position in Arcturus Therapeutics in Q2 2024 and held it in 1 quarter.
  • EntryPoint Capital's Arcturus Therapeutics position peaked at $297K in Q2 2024.
  • 164 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.